Asset Details
Do you wish to reserve the book?
EBMT activity survey 2004 and changes in disease indication over the past 15 years
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
EBMT activity survey 2004 and changes in disease indication over the past 15 years
Do you wish to request the book?
EBMT activity survey 2004 and changes in disease indication over the past 15 years
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
EBMT activity survey 2004 and changes in disease indication over the past 15 years
2006
Overview
This fifteenth annual European Group for Blood and Marrow Transplantation activity report lists the transplant activity in Europe in 2004 and documents the changes in indication over the past 15 years. In 2004, there were 22 216 first hematopoetic stem cells (HSCT), 7407 allogeneic (33%), 14 809 autologous (67%) and 4378 additional re- or multiple transplants reported from 592 centres in 38 European and five affiliated countries. Main indications were leukemias (7045 (32%; 78% allogeneic)); lymphomas (12 310 (55%; 94% autologous)); solid tumors (1759 (8%; 93% autologous)) and nonmalignant disorders (1015 (5%; 92% allogeneic)). In comparison, 145 teams from 20 countries performed 4234 HSCT (2137 allogeneic, 50%; 2097 autologous, 50%) in 1990. The overall increase was accompanied by major changes. Stem cell source changed from bone marrow to peripheral blood. More than one-third of allogeneic HSCT are now from unrelated donors. Reduced intensity conditioning is employed for one-third of allogeneic HSCT. Leukemias for allogeneic and lymphoproliferative disorders for autologous HSCT continue to increase. The decline in HSCT for chronic myeloid leukemia appears to level off for the first time since 1999. These data are informative for patient counselling and decision making for health care professionals.
Publisher
Nature Publishing Group UK,Nature Publishing Group
Subject
Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy
/ Biological and medical sciences
/ Blood
/ Bone marrow, stem cells transplantation. Graft versus host reaction
/ Europe
/ Female
/ Hematologic and hematopoietic diseases
/ Hematopoietic Stem Cell Transplantation - history
/ Humans
/ Immunoproliferative diseases
/ Leukemia
/ Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
/ Lymphoma
/ Male
/ Medicine
/ Surveys
/ Transfusions. Complications. Transfusion reactions. Cell and gene therapy
/ Transplantation Conditioning - history
/ Tumors
